Document is current
Any future updates will be listed below
-
Authors
Akin, Cem https://orcid.org/0000-0001-6301-4520
Arock, Michel https://orcid.org/0000-0002-3990-4408
Carter, Melody C. https://orcid.org/0000-0003-0379-5366
George, Tracy I. https://orcid.org/0000-0001-5478-7847
Valent, Peter https://orcid.org/0000-0003-0456-5095
- License Information
-
More Information
Article History
Accepted: 21 March 2025
First Online: 24 April 2025
Competing interests
: P.V. declares consultancy (honoraria) for Novartis, Blueprint, Cogent, Incyte, AOP Orphan, Stemline and Daiichi Sankyo. M.A. receives research grants from Blueprint; honoraria from AB Science, Blueprint and Novartis. T.I.G. declares consultancy for Incyte, Blueprint, Celgene/BMS and Cogent Biosciences. C.A. declares consultancy (honoraria) for Blueprint, Novartis, Cogent and Telios; research grant from Blueprint, Cogent and Telios; Investigator in clinical trial for Blueprint, Cogent and Telios. M.C.C. declares no competing interests.
